
Pre-made Nipocalimab benchmark antibody ( Whole mAb, anti-FCGRT therapeutic antibody, Anti-FCRN/FcgammaRn/alpha-chain Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-378
Pre-Made Nipocalimab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nipocalimab is a fully human, aglycosylated, effectorless immunoglobulin G1 (IgG) anti-FcRN antibody that functions to reduce the levels of other IgG antibodies in the blood, including the autoantibodies that cause gMG.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-378-1mg | 1mg | 3090 | ||
GMP-Bios-ab-378-10mg | 10mg | 21890 | ||
GMP-Bios-ab-378-100mg | 100mg | 148000 | ||
GMP-Bios-ab-378-xmg | >100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Nipocalimab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody |
INN Name | Nipocalimab |
Target | FCGRT |
Format | Whole mAb |
Derivation | |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Lambda |
Highest_Clin_Trial (Jan '20) | Phase-III |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | 5whk:HL/5whj:HL |
Year Proposed | 2019 |
Year Recommended | 2020 |
Companies | Momenta |
Conditions Approved | na |
Conditions Active | Autoimmune haemolytic anaemia;Haemolytic disease of newborn;Myasthenia gravis |
Conditions Discontinued | na |
Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
